This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (64)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Luis Alberto García Rodríguez, MD, MSc; Chiara Cattaruzzi, PharmD; Maria Grazia Troncon, PharmD; Luisa Agostinis

Arch Intern Med. 1998;158:33-39.

Background  Nonsteroidal anti-inflammatory drugs (NSAIDs) cause substantial morbidity and mortality from upper gastrointestinal tract disease. Ketorolac tromethamine has been singled out as an NSAID with a distinct gastrotoxicity profile. Calcium channel blockers, a class of antihypertensive drugs, have also been found to increase the risk of gastrointestinal tract bleeding.

Methods  We identified 1505 patients hospitalized because of upper gastrointestinal tract bleeding and/or perforation, and we randomly sampled 20000 controls in the source population.

Results  The adjusted relative risk (RR) for upper gastrointestinal tract bleeding and/or perforation in NSAID users compared with nonusers was 4.4 (95% confidence interval [CI], 3.7-5.3). The risk increased with higher daily doses. Ketorolac presented the highest risk (RR, 24.7; 95% CI, 9.6-63.5) and piroxicam ranked second (RR, 9.5; 95% CI, 6.5-13.8). Ketorolac was 5 times more gastrotoxic than all other NSAIDs (RR, 5.5; 95% CI, 2.1-14.4). The excess risk with ketorolac was observed with both oral and intramuscular administration and was already present during the first week of therapy. Among the various antihypertensive drug classes, -blockers were associated with the lowest relative risk (RR, 1.0; 95% CI, 0.7-1.4), and current use of calcium channel blockers with the highest (RR, 1.7; 95% CI, 1.3-2.1). The association with calcium channel blockers declined when adjusting for various markers of comorbidity (RR, 1.4; 95% CI, 1.1-1.8). Past use of calcium channel blockers was also associated with an increased risk (RR, 1.5; 95% CI, 1.3-1.8).

Conclusions  The excess risk of major upper gastrointestinal tract complications associated with outpatient use of ketorolac suggests an unfavorable risk-benefit assessment compared with other NSAIDs. More data are required to reduce the uncertainty about the apparent small increased risk of upper gastrointestinal tract bleeding in patients using calcium channel blockers.

From the Spanish Center for Pharmacoepidemiologic Research, Complutense University, Madrid, Spain (Dr García Rodríguez); Azienda Hospital "S. Maria della Misericordia," Udine, Italy (Dr Cattaruzzi); Regional Health Directorate, Trieste, Italy (Dr Troncon); and Insiel, Udine (Ms Agostinis).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Patrono et al.
Chest 2008;133:199S-233S.
ABSTRACT | FULL TEXT  

An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs
Ong et al.
Clin Med Res 2007;5:19-34.
ABSTRACT | FULL TEXT  

Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations
Lanas et al.
Gut 2006;55:1731-1738.
ABSTRACT | FULL TEXT  

Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population?
Elliott et al.
Rheumatology (Oxford) 2006;45:606-613.
ABSTRACT | FULL TEXT  

Low-dose aspirin for the prevention of atherothrombosis.
Patrono et al.
NEJM 2005;353:2373-2383.
FULL TEXT  

Nonsteroidal Anti-inflammatory Drugs and Risk of Esophageal and Gastric Cancer
Lindblad et al.
Cancer Epidemiol. Biomarkers Prev. 2005;14:444-450.
ABSTRACT | FULL TEXT  

Prospective study of elderly people comparing treatments following first primary care consultation for a symptomatic hip or knee
Linsell et al.
Fam Pract 2005;22:118-125.
ABSTRACT | FULL TEXT  

The Cyclooxygenase-2-Specific Inhibitor Parecoxib Sodium Is as Effective as 12 mg of Morphine Administered Intramuscularly for Treating Pain After Gynecologic Laparotomy Surgery
Malan et al.
Anesth. Analg. 2005;100:454-460.
ABSTRACT | FULL TEXT  

Postoperative naproxen after coronary artery bypass surgery: a double-blind randomized controlled trial
Kulik et al.
Eur. J. Cardiothorac. Surg. 2004;26:694-700.
ABSTRACT | FULL TEXT  

Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
Simmons et al.
Pharmacol. Rev. 2004;56:387-437.
ABSTRACT | FULL TEXT  

Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Patrono et al.
Chest 2004;126:234S-264S.
ABSTRACT | FULL TEXT  

Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach
Richy et al.
Ann Rheum Dis 2004;63:759-766.
ABSTRACT | FULL TEXT  

Expert Consensus Document on the Use of Antiplatelet Agents: The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology
Patrono et al.
Eur Heart J 2004;25:166-181.
FULL TEXT  

Risk of Uncomplicated Peptic Ulcer among Users of Aspirin and Nonaspirin Nonsteroidal Antiinflammatory Drugs
Garcia Rodriguez and Hernandez-Diaz
Am J Epidemiol 2004;159:23-31.
ABSTRACT | FULL TEXT  

Small risk ratios may have strong public health impact
Carvajal et al.
BMJ 2003;327:1050-1051.
FULL TEXT  

Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs
Traversa et al.
BMJ 2003;327:18-22.
ABSTRACT | FULL TEXT  

Pharmacoutilization and costs of osteoarthritis: changes induced by the introduction of a cyclooxygenase-2 inhibitor into clinical practice
Russo et al.
Rheumatology (Oxford) 2003;42:879-887.
ABSTRACT | FULL TEXT  

Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors
Hawkey and Langman
Gut 2003;52:600-608.
ABSTRACT | FULL TEXT  

Ketorolac, diclofenac, and ketoprofen are equally safe for pain relief after major surgery{dagger}
Forrest et al.
Br J Anaesth 2002;88:227-233.
ABSTRACT | FULL TEXT  

Antiplatelet strategies
Patrono
Eur Heart J Suppl 2002;4:A42-A47.
ABSTRACT  

The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald and Patrono
NEJM 2001;345:433-442.
FULL TEXT  

Steroids and Risk of Upper Gastrointestinal Complications
Hernandez-Diaz and Rodriguez
Am J Epidemiol 2001;153:1089-1093.
ABSTRACT | FULL TEXT  

Epidemiologic Review of the Calcium Channel Blocker Drugs: An Up-to-date Perspective on the Proposed Hazards
Kizer and Kimmel
Arch Intern Med 2001;161:1145-1158.
ABSTRACT | FULL TEXT  

Selective Inhibitors of Cyclooxygenase-2: A Growing Class of Anti-Inflammatory Drugs
Mardini and FitzGerald
Mol. Interv. 2001;1:30-38.
ABSTRACT | FULL TEXT  

Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects
Patrono et al.
Chest 2001;119:39S-63S.
FULL TEXT  

Safety and Efficacy of Meloxicam in the Treatment of Osteoarthritis: A 12-Week, Double-blind, Multiple-Dose, Placebo-Controlled Trial
Yocum et al.
Arch Intern Med 2000;160:2947-2954.
ABSTRACT | FULL TEXT  

Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial
Silverstein et al.
JAMA 2000;284:1247-1255.
ABSTRACT | FULL TEXT  

Association Between Nonsteroidal Anti-inflammatory Drugs and Upper Gastrointestinal Tract Bleeding/Perforation: An Overview of Epidemiologic Studies Published in the 1990s
Hernandez-Diaz and Rodriguez
Arch Intern Med 2000;160:2093-2099.
ABSTRACT | FULL TEXT  

Use of Calcium Channel Blockers and Risk of Hospitalized Gastrointestinal Tract Bleeding
Kaplan et al.
Arch Intern Med 2000;160:1849-1855.
ABSTRACT | FULL TEXT  

Unresolved Issues in the Role of Cyclooxygenase-2 in Normal Physiologic Processes and Disease
Lipsky et al.
Arch Intern Med 2000;160:913-920.
ABSTRACT | FULL TEXT  

Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
Brooks et al.
Rheumatology (Oxford) 1999;38:779-788.
ABSTRACT | FULL TEXT  

Dose-Dependent Inhibition of Platelet Cyclooxygenase-1 and Monocyte Cyclooxygenase-2 by Meloxicam in Healthy Subjects
Panara et al.
J. Pharmacol. Exp. Ther. 1999;290:276-280.
ABSTRACT | FULL TEXT  

A Double-Blinded Evaluation of Propacetamol Versus Ketorolac in Combination with Patient-Controlled Analgesia Morphine: Analgesic Efficacy and Tolerability After Gynecologic Surgery
Varrassi et al.
Anesth. Analg. 1999;88:611-611.
ABSTRACT | FULL TEXT